Balance Sheet DaShenLin Pharmaceutical Group Co., Ltd.

Revenues

Other Revenues, Total

Cost of Goods Sold, Total

Selling General & Admin Expenses, Total

Provision for Bad Debts

R&D Expenses

Other Operating Expenses

Other Operating Expenses, Total

Interest Expense, Total

Interest And Investment Income

Net Interest Expenses

Other Non Operating Income (Expenses)

Impairment of Goodwill

Gain (Loss) On Sale Of Investments

Gain (Loss) On Sale Of Assets

Asset Writedown

Other Unusual Items

Income Tax Expense

Net Income to Company

Minority Interest

Net Income to Common Incl Extra Items

Net Income to Common Excl. Extra Items

Net EPS - Basic

Basic EPS - Continuing Operations

Basic Weighted Average Shares Outstanding

Net EPS - Diluted

Diluted EPS - Continuing Operations

Diluted Weighted Average Shares Outstanding

Normalized Basic EPS

Normalized Diluted EPS

Dividend Per Share

Payout Ratio

EBITDA

EBITA

EBIT

EBITDAR

Total Revenues (As Reported)

Effective Tax Rate - (Ratio)

Current Domestic Taxes

Total Current Taxes

Deferred Domestic Taxes

Total Deferred Taxes

Normalized Net Income

Interest Capitalized

Interest on Long-Term Debt

Advertising Expense

Selling and Marketing Expenses

General and Administrative Expenses

Research And Development Expense From Footnotes

Net Rental Expense, Total

Imputed Operating Lease Interest Expense

Imputed Operating Lease Depreciation

Stock-Based Comp., G&A Exp. (Total)

Total Stock-Based Compensation

Net Income

Depreciation & Amortization - CF

Amortization of Goodwill and Intangible Assets - (CF)

Depreciation & Amortization, Total

Amortization of Deferred Charges, Total - (CF)

(Gain) Loss From Sale Of Asset

(Gain) Loss on Sale of Investments - (CF)

Asset Writedown & Restructuring Costs

Provision and Write-off of Bad Debts

Other Operating Activities, Total

Change In Accounts Receivable

Change In Inventories

Change In Accounts Payable

Change In Deferred Taxes

Change in Other Net Operating Assets

Capital Expenditure

Sale of Property, Plant, and Equipment

Cash Acquisitions

Divestitures

Investment in Marketable and Equity Securities, Total

Net (Increase) Decrease in Loans Originated / Sold - Investing

Other Investing Activities, Total

Short Term Debt Issued, Total

Long-Term Debt Issued, Total

Total Debt Issued

Short Term Debt Repaid, Total

Long-Term Debt Repaid, Total

Total Debt Repaid

Issuance of Common Stock

Repurchase of Common Stock

Common Dividends Paid

Common & Preferred Stock Dividends Paid

Other Financing Activities, Total

Foreign Exchange Rate Adjustments

Cash Interest Paid

Cash Income Tax Paid (Refund)

Change In Net Working Capital

Net Debt Issued / Repaid

Return on Assets

Return on Total Capital

Return On Equity %

Return on Common Equity

Gross Profit Margin %

SG&A Margin

EBITDA Margin %

EBITA Margin %

EBIT Margin %

Income From Continuing Operations Margin %

Net Income Margin %

Net Avail. For Common Margin %

Normalized Net Income Margin

Levered Free Cash Flow Margin

Unlevered Free Cash Flow Margin

Asset Turnover

Fixed Assets Turnover

Receivables Turnover (Average Receivables)

Inventory Turnover (Average Inventory)

Current Ratio

Quick Ratio

Operating Cash Flow to Current Liabilities

Days Sales Outstanding (Average Receivables)

Days Outstanding Inventory (Average Inventory)

Average Days Payable Outstanding

Cash Conversion Cycle (Average Days)

Total Debt/Equity

Total Debt / Total Capital

LT Debt/Equity

Long-Term Debt / Total Capital

Total Liabilities / Total Assets

EBIT / Interest Expense

EBITDA / Interest Expense

(EBITDA - Capex) / Interest Expense

Total Debt / EBITDA

Net Debt / EBITDA

Total Debt / (EBITDA - Capex)

Net Debt / (EBITDA - Capex)

Total Revenues, 1 Yr. Growth %

Gross Profit, 1 Yr. Growth %

EBITDA, 1 Yr. Growth %

EBITA, 1 Yr. Growth %